Citigroup Inc Senseonics Holdings, Inc. Transaction History

Citigroup Inc

$163 Billion
Q4 2024

A detailed history of Citigroup Inc transactions in Senseonics Holdings, Inc. stock. As of the latest transaction made, Citigroup Inc holds 46,843 shares of SENS stock, worth $32,321. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,843

Previous 39,539 18.47%

Holding current value

$32,321

Previous $13,000 84.62%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$0.25 - $0.59 $1,826 - $4,309	7,304 Added 18.47%	46,843 $24,000
Q3 2024 Nov 12, 2024	BUY	$0.32 - $0.49 $112 - $172	352 Added 0.9%	39,539 $13,000
Q2 2024 Aug 12, 2024	SELL	$0.37 - $0.52 $5 - $8	-16 Reduced 0.04%	39,187 $15,000
Q4 2023 Feb 09, 2024	BUY	$0.48 - $0.7 $6,000 - $8,750	12,500 Added 46.81%	39,203 $22,000
Q3 2023 Nov 09, 2023	BUY	$0.5 - $1.05 $1,108 - $2,326	2,216 Added 9.05%	26,703 $16,000
Q2 2023 Aug 10, 2023	SELL	$0.55 - $0.89 $6,228 - $10,078	-11,324 Reduced 31.62%	24,487 $18,000
Q1 2023 May 11, 2023	BUY	$0.68 - $1.25 $841 - $1,546	1,237 Added 3.58%	35,811 $25,000
Q4 2022 Feb 09, 2023	SELL	$0.96 - $1.34 $12,871 - $17,966	-13,408 Reduced 27.94%	34,574 $35,000
Q3 2022 Nov 10, 2022	SELL	$1.02 - $2.23 $48,815 - $106,723	-47,858 Reduced 49.94%	47,982 $64,000
Q2 2022 Aug 10, 2022	BUY	$0.94 - $1.94 $908 - $1,874	966 Added 1.02%	95,840 $98,000
Q1 2022 May 12, 2022	SELL	$1.54 - $3.71 $130,009 - $313,205	-84,422 Reduced 47.09%	94,874 $187,000
Q4 2021 Feb 10, 2022	BUY	$2.58 - $3.91 $181,515 - $275,088	70,355 Added 64.58%	179,296 $478,000
Q3 2021 Nov 10, 2021	BUY	$2.77 - $4.05 $301,766 - $441,211	108,941 New	108,941 $369,000

Others Institutions Holding SENS

# of Institutions

138

Shares Held

80.6M

Call Options Held

418K

Put Options Held

219K

View Full List

About Senseonics Holdings, Inc.

Ticker SENS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 465,447,008
Market Cap $321M
Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with ...

More about SENS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account